Kura Oncology 

Kura Oncology, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to discovering and advancing cancer treatments within the United States. Its therapeutic portfolio primarily features small-molecule compounds engineered to combat various cancers. Among its leading drug candidates is ziftomenib, a small-molecule agent designed to disrupt the interaction of menin-Lysine K-specific Methyltransferase 2A proteins. This inhibitor is being developed for specific genetic forms of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Another prominent candidate is tipifarnib, an orally administered farnesyl transferase inhibitor currently undergoing Phase II clinical assessment for both solid tumors and blood-related conditions. The company has also established a clinical collaboration with Novartis to evaluate the combined therapeutic potential of tipifarnib and alpelisib. This joint effort targets patients with head and neck squamous cell carcinoma whose tumors exhibit HRAS overexpression or specific PIK3CA mutations or amplifications. Founded in 2014, Kura Oncology, Inc. operates from its headquarters in San Diego, California.